Azacitidine
Measurable Disease
Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Measurable Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Risperdal National Institute of Mental Health and Neuro Sciences, India | Phase 4 | BB |
CITALOPRAM National Institute of Mental Health and Neuro Sciences, India | Phase 4 | BB |
Vortioxetine Northwell Health | Phase 4 | BB |
Guarana Extract Faculdade de Medicina do ABC | Phase 2 | B |
BRADANICLINE Targacept Inc. | Phase 2 | B |
View all 11 →
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →